Marengo Therapeutics, an ATP company, and King’s College London are collaborating on research into T cell activation and regulation under the aegis of a strategic research agreement. Basic research activities are being conducted by scientists from Marengo and King’s College London, under the supervision and leadership of Professor Adrian Hayday, Kay Glendinning Professor of Immunobiology at King’s College London.
Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ). The study will aim to connect individual symptoms to specific brain-circuit dysfunctions, and will inform the development of novel therapies that target the underlying neurobiological processes of individual behavioral traits.